Scisparc announces u.s. patent application for treating metabolic syndrome and weight loss

Tel aviv, israel, july 16, 2024 (globe newswire) -- scisparc ltd. (nasdaq: sprc) ("company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that an additional patent application with the united states patent and trademark office (“uspto”) was submitted as part of its ongoing collaboration with clearmind medicine inc. (nasdaq: cmnd), (fse: cwy0) (“clearmind"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems and invented with professor joseph tam from the hebrew university's technology transfer company, yissum. the patent application is for the novel proprietary composition of palmitoylethanolamide (“pea”), the active ingredient of scisparc's proprietary cannamide™ with clearmind's innovative meai compound (5-methoxy-2-aminoindane) for treating metabolic syndrome and obesity.
SPRC Ratings Summary
SPRC Quant Ranking